Age Progression of Neuropathological Markers in the Brain of the Chilean Rodent Octodon degus, a Natural Model of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder and the leading cause of age‐related dementia worldwide. Several models for AD have been developed to provide information regarding the initial changes that lead to degeneration. Transgenic mouse models recapitulate many, but not all, of the features of AD, most likely because of the high complexity of the pathology. In this context, the validation of a wild‐type animal model of AD that mimics the neuropathological and behavioral abnormalities is necessary. In previous studies, we have reported that the Chilean rodent Octodon degus could represent a natural model for AD. In the present work, we further describe the age‐related neurodegeneration observed in the O. degus brain. We report some histopathological markers associated with the onset progression of AD, such as glial activation, increase in oxidative stress markers, neuronal apoptosis and the expression of the peroxisome proliferative‐activated receptor γ coactivator‐1α (PGC‐1α). With these results, we suggest that the O. degus could represent a new model for AD research and a powerful tool in the search for therapeutic strategies against AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“Different cellular and histopathological biomarkers have been described, including amyloid plaques, neurofibrillary tangles (NFTs), increased production of reactive oxygen species (ROS), mitochondrial dysfunction, decreased cerebral glucose consumption and altered autophagy processes (13, 29, 36, 40, 54, 75).”
BackgroundThe role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“Moreover, the overexpression of human transgenes in a nonphysiological scenario strongly influences the onset of histopathological features and cognitive decline observed in AD (16, 58).”
BackgroundSpilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033 · cited 1×
“These proteins are critical in pre-autophagosomal membrane formation and autophagy is deregulated in AD (55, 78).”
BackgroundMacroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease
Yu, W. H., Cuervo, A. M., Kumar, A., Peterhoff, C. M., Schmidt, S. D., Lee, J.-H., Mohan, P. S., Mercken, M., Farmery, M. R., Tjernberg, L. O., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505082 · Cited by 967
Oxidative Stress and the Pathogenesis of Alzheimer's Disease
Zhao, Y., & Zhao, B. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/316523 · Cited by 855 · cited 3×
“Several groups have described that mitochondrial failure is a critical step in the progression of AD because of its fundamental role in neuronal metabolism (24, 83, 89).”
BackgroundMolecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772 · cited 1×
“Moreover, the overexpression of human transgenes in a nonphysiological scenario strongly influences the onset of histopathological features and cognitive decline observed in AD (16, 58).”
BackgroundWebster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., & Van Eldik, L. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00088 · Cited by 755 · cited 1×
“However, these models do not recapitulate the entire spectrum of lesions present in human AD brains (17, 42, 84).”
BackgroundMitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology
Moreira, P. I., Carvalho, C., Zhu, X., Smith, M. A., & Perry, G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.006 · Cited by 734
Microglial dysfunction in brain aging and Alzheimer's disease
Mosher, K. I., & Wyss-Coray, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.008 · Cited by 618 · cited 2×
“The activation of astrocytes and microglia has been described in several models of neurodegenerative disease and has been postulated to represent a common alteration in AD in response to neuronal damage (37, 56).”
BackgroundOxidative stress hypothesis in Alzheimer’s disease: a reappraisal
Praticò, D. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.09.001 · Cited by 606 · cited 1×
“In fact, the damage induced by oxidative stress in the hippocampus has been suggested as critical to the failure of cognitive performance in AD patients (62, 64, 79, 89).”
BackgroundKapogiannis, D., & Mattson, M. P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70277-5 · Cited by 594
Synapses and Alzheimer's Disease
Sheng, M., Sabatini, B. L., & Sudhof, T. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005777 · Cited by 436 · cited 1×
“The role of casp-3 activation in AD has been recently emphasized in vitro in Aβ-challenged neurons and the brains of individuals with AD (76).”
BackgroundAnimal Models of Alzheimer Disease
LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419
Neuroprotective strategies involving ROS in Alzheimer disease
Dumont, M., & Beal, M. F. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.11.026 · Cited by 402
The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer’s disease
Miranda, S., Opazo, C., Larrondo, L. F., Muñoz, F. J., Ruiz, F., Leighton, F., & Inestrosa, N. C. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00015-0 · Cited by 369
Self-citationNeuronal cell death in neurodegenerative diseases: recurring themes around protein handling
Gorman, A. M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00402.x · Cited by 362 · cited 1×
“Apoptosis has been associated with several neurodegenerative pathologies (26).”
BackgroundMicroglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291 · cited 1×
“Increased astrogliosis and microgliosis is an undisputed feature of AD brains with increased Aβ loads (49, 65).”
BackgroundSuccessful therapies for Alzheimer’s disease: why so many in animal models and none in humans?
Franco, R., & Cedazo-Minguez, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00146 · Cited by 183
Kitazawa, M., Medeiros, R., & M. LaFerla, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315786 · Cited by 178 · cited 1×
“Even though these models are widely used, the rate of success of new therapeutic intervention strategies or therapeutic alternatives derived from the models is quite poor (12, 23, 38, 42, 46).”
BackgroundInterleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options
Hüll, M., Fiebich, B. L., Lieb, K., Strauss, S., Berger, M., Volk, B., & Bauer, J. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00107-8 · Cited by 82
Cited by
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226
“Thus, stimulating Wnt/β-catenin signaling could represent an interesting therapeutic target for AD [15,16].”
BackgroundActin dynamics and cofilin‐actin rods in alzheimer disease
Bamburg, J. R., & Bernstein, B. W. (2016) · Cytoskeleton · doi:10.1002/cm.21282 · Cited by 181
Revisiting rodent models: Octodon degus as Alzheimer’s disease model?
Steffen, J., Krohn, M., Paarmann, K., Schwitlick, C., Brüning, T., Marreiros, R., Müller-Schiffmann, A., Korth, C., Braun, K., & Pahnke, J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0363-y · Cited by 62
“However, the most recent study, analysing young (1 to 3 years old) and old animals (4 to 6 years old), found AD associated autophagy markers LC3 and p62 unchanged [15].”
InfluentialWnt signaling pathway dysregulation in the aging brain: lessons from the Octodon degus
Inestrosa, N. C., Tapia-Rojas, C., Lindsay, C. B., & Zolezzi, J. M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00734 · Cited by 43
Self-citation
Metadata
- Authors
- Inestrosa, N. C., Ríos, J. A., Cisternas, P., Tapia‐Rojas, C., Rivera, D. S., Braidy, N., Zolezzi, J. M., Godoy, J. A., Carvajal, F. J., Ardiles, A. O., Bozinovic, F., Palacios, A. G., & Sachdev, P. S.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2015-02-10
- Volume
- 25
- Issue
- 6
- Pages
- 679-691
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W2129703919
- Cited by
- 44
- References
- 21
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.